Equillium, Inc. Common Stock (EQ)

Price$2.94

Value ScoreB

Growth ScoreF

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)218.74%

Price vs S&P 500 (4W)39.35%

VGM Score52.46

Market Capitalization$185.89M

All Metrics

Book Value / Share (Quarterly)$0.94

P/TBV (Annual)0.56x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.30

Price vs S&P 500 (YTD)81.52%

Net Profit Margin (TTM)-19.62%

EPS (TTM)$-0.32

10-Day Avg Trading Volume1.89M

EPS Excl Extra (TTM)$-0.32

EPS (Annual)$-0.39

ROI (Annual)-75.86%

Net Profit Margin (5Y Avg)-1079.66%

Cash / Share (Quarterly)$0.97

ROA (Last FY)-68.75%

Revenue Growth TTM (YoY)-90.43%

EBITD / Share (TTM)$-0.28

ROE (5Y Avg)-85.80%

Operating Margin (TTM)-20.13%

Cash Flow / Share (Annual)$-0.38

P/B Ratio3.13x

P/B Ratio (Quarterly)2.13x

Net Income / Employee (Annual)$-1,692,300

EV / Revenue (TTM)3.03x

Net Interest Coverage (TTM)-98.10x

ROA (TTM)-53.69%

EPS Incl Extra (Annual)$-0.39

Current Ratio (Annual)10.58x

Quick Ratio (Quarterly)18.22x

3-Month Avg Trading Volume0.61M

52-Week Price Return716.67%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.69

P/S Ratio (Annual)4.52x

Asset Turnover (Annual)1.58x

52-Week High$3.45

Operating Margin (5Y Avg)-1045.45%

EPS Excl Extra (Annual)$-0.39

CapEx CAGR (5Y)-24.21%

26-Week Price Return226.67%

Quick Ratio (Annual)10.43x

13-Week Price Return67.05%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)18.51x

Enterprise Value$124.56M

Asset Turnover (TTM)1.12x

Book Value / Share Growth (5Y)-30.11%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-18.76%

Cash / Share (Annual)$0.50

3-Month Return Std Dev113.75%

Net Income / Employee (TTM)$-1,466,200

ROE (Last FY)-75.86%

Net Interest Coverage (Annual)-96.56x

EPS Basic Excl Extra (Annual)$-0.39

P/FCF (TTM)1.55x

Receivables Turnover (TTM)22.01x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.32

ROI (TTM)-61.45%

P/S Ratio (TTM)4.52x

Pretax Margin (5Y Avg)-1079.66%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.93

Price vs S&P 500 (52W)692.30%

Year-to-Date Return89.68%

5-Day Price Return-4.55%

EPS Normalized (Annual)$-0.39

ROA (5Y Avg)-50.12%

Net Profit Margin (Annual)-19.64%

Month-to-Date Return1.38%

Cash Flow / Share (TTM)$-0.23

EBITD / Share (Annual)$-0.42

Operating Margin (Annual)-20.12%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-75.69%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.32

P/TBV (Quarterly)0.74x

P/B Ratio (Annual)3.29x

Pretax Margin (TTM)-18.75%

Book Value / Share (Annual)$0.47

Price vs S&P 500 (13W)58.79%

Beta1.85x

Revenue / Share (TTM)$0.00

ROE (TTM)-61.45%

52-Week Low$0.27

vGradeB

gGradeF

mGradeA

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.06est. -0.04

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.27

4.25

4.31

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
EQEquillium, Inc. Common Stock	B	F	A	$2.94
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Equillium is a clinical-stage biotechnology company developing novel immunotherapies for severe autoimmune and inflammatory disorders. Its lead candidate, Itolizumab (EQ001), is an anti-CD6 monoclonal antibody designed to modulate pathogenic immune responses while preserving regulatory T cells. The company plans to commercialize its pipeline through partnerships, independent development, or strategic transactions. Additional candidates include EQ101 and EQ302.